Novel Coronavirus (SARS-CoV-2/COVID-19)
The Department of Health and Human Services announced a $3 billion investment in antiviral treatments for COVID-19, particularly those administered orally. The money will go toward advancing the next stages of COVID-19 treatments, including their discovery, development and manufacturing.
The AHA joined the U.S. Chamber of Commerce and other national organizations in urging the 9th Circuit Court of Appeals to affirm a district court decision that found the Public Readiness and Emergency Preparedness Act of 2005 provides broad immunity from tort liability to health care providers and…
A National Institutes of Health-led review of more than 24,000 stored blood samples suggests that the coronavirus that causes COVID-19 was present in the U.S. as far back as December 2019.
The Food and Drug Administration authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of the SARS-CoV-2 P.1 and B.1.351 variants, which are not susceptible to the combination therapy, the Department of Health and Human Services’…
As requested by the AHA, the Centers for Medicare & Medicaid Services said it will continue to remain flexible in its approach to surveys if a hospital experiences a COVID-19 surge.
The Living Learning Network’s pandemic reflection book showcases the defining moments of COVID-19 as told by the front lines.
The Centers for Disease Control and Prevention released a COVID-19 Viral Testing Tool to help health care providers and individuals understand their COVID-19 testing options and take appropriate next steps.
The Health Resources and Services Administration awarded 14 organizations grants to hire people to support COVID-19 vaccination and outreach in vulnerable and medically underserved communities.
Novavax announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy.